Homeopathy as a Protective Factor to Covid-19

Preliminary Study of Symptoms and Prevalent Medicines of the Viral Respiratory Syndrome Epidemic Genius of the Covid-19 Pandemic in Campo Grande/MS - Use of homeopathy as an Additional Protection Factor

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

REBEC

Registry ID

RBR-84nk5q6

Enrollment

Unknown

Registered

2021-05-20

Start date

2020-11-23

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus Infections

Interventions

Clinical Study, Randomized, Placebo, Controlled The objective of the researchis to evaluate the efficacy and safety of the homeopathic medicine “Metallum album 30CH” (Arsenicum album) as a protective

HP4.018.127.521

Eligibility

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Both sex; age over 18 and under 80 years; person not using other drugs prophylactically for the disease; absence of nonspecific respiratory syndrome in the last 14 days; no living with confirmed case of COVID-19; no positive test to RTP PCR-Covid-19.

Exclusion criteria

Exclusion criteria: Under 18 and or over 80 years; respiratory syndrome in the last 14 days; Positive test to COVID-19; use other preventive drugs to COVID-19; living with a confirmed case of COVID-19.

Design outcomes

Primary

Measure	Time frame
Incidence of severe case of COVID-19 in the period between 15 days and up to 03 months from the first medication intake.	—

Secondary

Measure	Time frame
Incidence of serious adverse events (drug safety).	—

Countries

Brazil

Contacts

Public ContactJoaquim Longo

joaquim.longo@ufms.br+55-67-33457187

Outcome results

None listed

Source: REBEC (via WHO ICTRP)